[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649997":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":29,"locations":10,"responsibleParty":35,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":10},{"fullName":5,"class":6},"CanSino Biologics Inc.","INDUSTRY",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Previously vaccinated with MCV4 (CanSino)",null,[12],"Other: Previously vaccinated with MCV4 (CanSino)",{"label":14,"type":10,"description":10,"interventionNames":15},"Previously vaccinated with MPSV4 (LvZhu)",[16],"Other: Previously vaccinated with MPSV4 (LvZhu)",[18,22],{"type":19,"name":9,"description":20,"armGroupLabels":21,"otherNames":10},"OTHER","3.0 to 4.0 mL of venous blood will be collected for the immunodynamic study at 3 and 5 years after vaccination",[9],{"type":19,"name":14,"description":20,"armGroupLabels":23,"otherNames":10},[14],[25],{"name":26,"affiliation":27,"role":28},"Xiaoyu Liu","Center for Disease Prevention and Control, Shaanxi Province","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Shiwen Xu","CONTACT","022-58213600-6051","shiwen.xu@cansinotech.com",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100649997","a-clinical-trial-of-the-acyw135-group-meningococcal-polysaccharide-conjugated-vaccine-crm197-vector-100649997",false,"NCT07743411","A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)","Phase IV Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)","Inclusion Criteria:\n\n* Individuals who previously participated in the Phase IIIb clinical trial of the ACYW135 group meningococcal polysaccharide-conjugated vaccine (CRM197 carrier) for children aged 4-6 years (Protocol No.: CTP-MCVF-002) and were included in both the IPS1 and IPS2 analysis sets\n* Willing to provide identification documents\n* Willing to provide informed consent, voluntarily sign the informed consent form, and comply with the requirements of the clinical study protocol\n* The interval since completion of the vaccination series must be at least 3 years\n\nExclusion Criteria:\n\n* Received another meningococcal vaccine after completion of the CTP-MCVF-002 trial\n* Has thrombocytopenia, any coagulation disorder, or is currently receiving anticoagulant therapy\n* Has a history of meningitis since the end of the CTP-MCVF-002 trial\n* Other conditions deemed by the investigator to make the subject ineligible for this clinical study",true,"ALL","7 Years","9 Years",{"count":49,"type":50},180,"ESTIMATED","OBSERVATIONAL","This study included 180 trial participants who had previously taken part in the Phase IIIb clinical trial of the ACYW135 group meningococcal polysaccharide-conjugated vaccine (CRM197 carrier) for children aged 4-6 years (Protocol No.: CTP-MCVF-002) and had completed blood sample collection at 90 and 180 days post-vaccination; there were 90 participants in each of the treatment and control groups. All trial participants were required to provide 3.0-4.0 mL of blood samples for immunopersistence assessment at 3 and 5 years post-vaccination, respectively.",[54],"Epidemic Meningitis",[56,57,58],"ACYW135","CRM197","Immunopersistence","NOT_YET_RECRUITING","2026-07-29",{"date":62,"type":63},"2026-08-03","ACTUAL",{"date":65,"type":50},"2026-09-15",{"date":67,"type":50},"2028-09-15",{"name":5,"class":6}]